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Abstract 
The paper deals with the so far most efficient antidiabetic transition metal compound family. 
It focuses on the species distribution of the most frequently studied vanadium(IV,V) 
compounds in biology: in the gastro-intestinal tract (being important in absorption of the 
compounds), the blood serum (very likely the main route of their transport), the whole blood 
(recently the role of the red blood cells are also assumed in their transport) and in the cells 
(where glutathione and ATP may be the most important redox and complex formation 
partners of the original vanadium-“insulinomimetics”). 
The discussed details fit into the general view, but far from a complete and clear 
understanding of the pharmacodynamics of these antidiabetics. A lot more in vitro and mostly 
in vivo studies are necessary to justify their real clinical use. 
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1. Introduction 
Progress in the bioinorganic chemistry of vanadium and the search in the therapeutic 
applications have been exponential and numerous reviews have been published in recent years 
[1-8]. Vanadium compounds have been shown to be potentially effective against diabetes, 
malign tumors including cancer, endemic tropical diseases (such as trypanosomiasis, 
leishmaniasis and amoebiasis), bacterial infections (tuberculosis and pneumonia) and HIV 
infections. Furthermore, vanadium drugs can be operative in cardio- and neuro-protection. So 
far, vanadium compounds have not yet been approved as pharmaceuticals for clinical use [1]. 
In this paper we will review the antidiabetic effects of vanadium compounds; other terms as 
insulin mimetic or insulin-enhancing are also used in the literature. However it is believed that 
in the complete lack of insulin (how can it be achieved in a living organism?) vanadium is not 
showing any insulin like effects, accordingly vanadium can only enhance the effects of insulin 
[2]. For this reason mostly we use the rather neutral antidiabetic expression for the blood 
glucose lowering effect (as one of the most important role of insulin in biology) of vanadium 
compounds. 
 
2. Insulin enhancing metal complexes in biological fluids 
Diabetes mellitus (‘diabetes’ or DM) is a group of metabolic diseases in which there is 
high blood sugar level over a prolonged, sometimes nearly a lifetime period. It is induced by a 
non-existent or insufficient insulin supply, or inadequate response to insulin. In the case of 
DM type 1 the insulin-producing cells in the body have been destroyed, while in the case of 
DM type 2 the cells of the body are not responding properly (partial resistance) to the insulin 
produced. As of 2015, an estimated 415 million people had diabetes worldwide with type 2 
DM [9], which usually appears in people over the age of 40, making up about 90% of the 
cases [10]. Type 1 diabetes can be treated only with insulin, a natural peptide (protein) 
hormone composed of 51 amino acids, also over 40% of patients with type 2 diabetes require, 
as part of their treatment, insulin injections. However, peptides currently cannot be taken 
orally because of their degradation in the GI tract, insulin is given as an injection [11]. This 
painful and expensive treatment could be replaced by an insulin ’mimicker’ which can be 
taken orally. Many metal ions such as Cr(III), Mn(II), Mo(VI), Se(V), V(IV/V), W(VI) and 
Zn(II) have insulin-like effect. 
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2.1. Insulin-enhancing vanadium compounds 
Although most foods contain low concentrations of vanadium (0.1 ng g–1), food is the 
major source of exposure to vanadium for the general population. The absorption of vanadium 
salts from the gastro-intestinal tract is poor in humans, and the excretion of Vanadium in the 
kidneys is relatively rapid with a half-life of 20–40 h in urine. Therefore, the toxicity of 
vanadium compounds is low in general. The estimated vanadium intake of the US population 
ranges from 10–60 mg V day–1. VO(IV)SO4 is a common supplement used to enhance weight 
training in athletes at doses of up to 60 mg day–1. In humans, the threshold level for vanadium 
toxicity is concluded to be approximately 10–20 mg V day–1 [4]. 
Insulin-like effects of vanadium were first demonstrated in vivo by McNeill and co-
workers [12] by simple adding of sodium orthovanadate (Na3VO4) to the drinking water of 
streptozotocin (STZ)-diabetic rats for several weeks. Later the only partly soluble vanadates 
were replaced by VO(IV)SO4 and the result was fewer negative side effects [13-15]. However 
the applied necessary dose of vanadium still was close to the levels at which adverse effects 
are observed [16]. The question became then, ‘‘is there some way to chemically improve 
potency of these drug candidate antidiabetic agents?’’. Several vanadium complexes with 
different coordination mode were synthesized and characterized in order to answer this 
question. The most frequent basic structures (‘backbones’) are depicted in Fig. 1. A key 
compound in this regard is the bis(maltolato)oxovanadiumV(IV) complex (VO(IV)(mal)2 or 
BMOV) [17,18], in Fig. 1, and its derivative the ethylmaltol complex [2] and allixin [19,20]. 
The related complex with the pyridinone complex VO(IV)(dhp)2 have also been prospective 
therapeutics [21]. Several other complexes have been studied, such as VO(IV)(acac)2, 
VO(IV)(pic)2, VO(IV)(hpno)2, VO(IV)(mpno)2, VO(IV)(metf)2 (the bis complex of 
metformin an antidiabetics itself) and several picolinato and dipicolinato derivatives. Most of 
them are neutral bis complexes formed with bidentate organic ligands (Table 1a and 1b), 
where the oxidation state of the vanadium is +4. One exception (Table 1c) is the 
[VO2(V)(dipic)]
‒ with negative charge and +5 oxidation state of the central metal ion [22]. All 
these complexes are labile, and ready to take part in fast ligand exchange reactions. 
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Table 1a Successful insulin mimetic in vivo tests with VO(IV)L2 complexes where the 
ligands (L) have (O,O) donor set 
L Dose Duration 
Blood glucose level (mM)  
/ animal model 
   
 
mmol V / kg 
/day 
days 
STZ 
rat 
STZ 
mice 
ZDF 
rat 
KKA' 
mice 
Ref 
comp. 
Ref. 
value 
Ref. 
   oa i.p.b  oa oa  (mM/%)  
mal type:          
imal 0.6 1 17(3)     BMOV 14(2) [23] 
emal 0.6 1  6.5(1.7)    BMOV 7.1(1.6) [24] 
emal 0.1 18    ~22    [25] 
ipmal 0.1 1 ~13     BMOV ~12 [24] 
alx 0.06/0.14 30     ~10   [26] 
alx 0.1/0.06/0.02 6   ~10b   BMOV ~15b [19] 
alx 0.14 9   ~12a     [20] 
hpno type:          
hpno 0.15 20 ~10       [27] 
hpno 0.05 8  ~8      [27] 
hopy type:          
mhopy 0.02-0.1 14 ~12       [28] 
dmhopy 0.1/0.08 14  ~11      [29] 
acac type:          
cur 0.1 2 
no 
eff. 
l.r.c 
(~14%) 
   BMOV 47% [30] 
a Oral gavage 
b Intraperitoneal injection 
c Low response (% decrease) 
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Table 1b Successful insulin mimetic in vivo tests with VO(IV)L2 complexes where the 
ligands (L) have (O,N) or (O,S) or (N,N) donor set 
 Dose Duration Glucose level (mM) / animal model    
L mmol V / kg /day days STZ rat KKA' mice 
Ref 
comp. 
Ref. 
value 
Ref. 
   oa i.p.b oa i.p.b  (mM)  
pic type (O,N donors):         
pic 0.48 42 14(2)      [31] 
pic 0.06   16(1)     [31] 
pic 0.2/0.1 14 8.5/8.1 
8.1(1.3)/ 
12 
    [32]  
6mpic 0.06/0.02 14  ~10     [33] 
6mpic 0.2/0.1 100 ~10      [33] 
6mpic 0.05 12    ~14 VOSO4 ~22 [34] 
6mpic 0.2 14   ~17    [34] 
6mpic 0.06/0.04/0.02 14  12(3)     [35] 
6etpic 0.05/0.04 13    ~10   [36] 
5ipic 0.1/0.05/0.02 28 /14 8(3) 10.7(6)     [37] 
3mpic 0.1/0.05/0.02 14  6.1(2)     [35] 
3hpic 0.1/0.05/0.02 14  6.1(1.5)     [35] 
mpno type (O,S donors):         
mpno 0.2 20 ~8      [27] 
mpno 0.05 8  ~9     [27] 
biguad type (N,N donors):         
metf 0.6 3 < 10    BMOV ~11 [38] 
metf 0.12 3  ~18   BMOV ~10 [38] 
a Oral gavage 
b Intraperitoneal injection 
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Table 1c Successful insulin mimetic in vivo tests with complexes having other than VO(IV)L2 
composition (L = ligand) 
 
a Oral gavage 
b Intraperitoneal injection 
Compounds 
compositions 
L 
Dose Duration 
Glucose level 
(mM) / animal 
model Ref comp. 
Ref. 
value 
(mM) 
Ref. 
mmol V / kg 
/day 
days 
STZ rat 
oa i.pb   
VO(IV)L dipic type, (O,N,O donors)        
 dipic not given 28 ~21  VO(IV)SO4 ~15 [39] 
V(III)L2 dipic type, (O,N,O donors)       
 dipic not given 28 ~18  VO(IV)SO4 ~15 [39] 
V(III)L3 mal type, (O,O donors)       
 imal 0.1 1  17(3) BMOV 11(4) [23] 
 amal 0.1 1  16(3) BMOV 14(4) [23] 
 mal 0.6a / 0.1b 1 15(3) 12(4) BMOV 
16(2)a / 
8(3)b 
[40] 
 emal 0.6a / 0.1b 1 19(3) 11(2) BMOV 
16(2)a / 
8(3)b 
[40] 
 koj 0.1 1  20(1) BMOV 8(3) [40] 
 dhp type, (O,O donors)       
 dhp 0.1 1  20(1) BMOV 8(3) [40] 
VO2(V)L
- dipic type, (O,N,O donors)       
 dipic not given 28 ~12.5  VO(IV)SO4 ~15 [39] 
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Fig. 1. Basic structure of insulin mimetic vanadium complexes studied in detail. (The water molecules 
in the coordination sphere are omitted.) 
 
One comparative study of some of these drug candidate vanadium complexes has been 
made, and it was pointed out that these complexes have 30–70% of the activity of insulin in 
insulin-depleted mice fibroblast cell culture tests [41]. Based on that publication it would be 
impossible to differentiate between the effectiveness of the vanadium compounds studied. 
Similar result, the small efficacy difference between the vanadium compounds can be 
concluded from Table 1. The decreased polarity can increase the insulin mimetic activity, but 
just until a certain limit [19]. 
Only one of these compounds were tested in humans: the Phase I clinical trial [16] of 
bis(ethylmaltolato)oxovanadium(IV) (BEOV, the ethyl- derivative of VO(IV)(maltolato)2) 
was completed in 2000, and the results of the Phase IIa clinical trial were first published in 
2009 [2]. The clinical Phase I trials proved that an orally administered 10-90 mg BEOV single 
dose is safe and tolerable by healthy people, overall bioavailability of vanadium from BEOV 
was three times higher than that of vanadium from VO(IV)SO4 and fasted subjects absorbed 
vanadium thirteen times better than fed subjects [16]. 
In Phase IIa tests over the course of a 28-day treatment period (daily dose 20 mg 
complex: 5.8 mol or 3 mg vanadium), BEOV was consistently well-tolerated. A positive 
treatment effect was observed in most of the treated subjects, such that reductions in fasting 
blood glucose were observed when compared to the two placebo subjects [2]. The tests have, 
however, been abandoned due to renal problems with some of the probands [42]. 
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The orally administered vanadium complex should go first through the GI tract and after 
the blood serum before arriving to the targeted cell. Biotransformation is possible in the entire 
route, and the absorption efficacy from the GI tract can be improved by formulation of the 
drug including various encapsulation techniques [43]. In spite the fact of the promising animal 
results these did not lead to any clinical tests with humans. However, the original carrier 
ligand is very likely to be replaced by serum/plasma components or endogenous binding 
molecules, before the cells would be able to take up the complex. 
The active species is vanadate (H2VO4
-) most likely, one possible final product of the 
biotransformation of any kind of vanadium compound. The possible mode of action is the 
inhibition of protein tyrosine phosphatases at the cytosolic site of the cellular insulin receptor 
and/or the activation of a tyrosine kinase in the signaling pathway [44]. It has also been 
proposed that cellular redox processes, increases production of ROS is also involved in the 
antidiabetic effects of the vanadium compounds [45,46]. 
 
2.2. Speciation of vanadium complexes in the gastrointestinal (GI) tract 
Based on speciation studies [6,8] it is clear that in consequence of the parallel processes 
of protonation of the metal-binding sites of the coordinating ligands, the neutral bis 
complexes (VO(IV)(mal)2 [47]. VO(IV)(dhp)2 [48], VO(IV)(pic)2 [49], VO(IV)(mpno)2 [50], 
VO(IV)(acac)2 [51] and their derivatives) will certainly partly decompose in the acidic pH 
range, e.g. at the pH (ca. 2) of the gastric juice. The species formed in this way will be 
charged, and will possess entirely different membrane transport properties. The 
[VO2(V)(dipic)]
– complex is stable at pH 2 [22] but it has already a ‒1 charge. 
Recently a useful speciation method, assessment of the chemical states of V, in 
biological environments was published [52]. Classification can be done on the basis of a 
three-dimensional diagrams of pre-edge and edge parameters in X-ray absorption near edge 
structure (XANES) spectra, developed on the basis of a library of model V(V/IV/III) 
complexes. Based on this method XANES results reported the speciation of four vanadium 
compounds mimicking oral administration by artificial digestion [53], although the applied 
vanadium concentration was fairly high, namely 1.0 mM. (Artificial gastric/intestinal juice 
has been prepared; incubations and commercial liquid semi-synthetic meals were used.) 
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Fig. 2. Proposed biotransformation of the initial vanadium compounds in GI environment based on 
XANES data taken after artificial digestion. (cV = 1.0 mM) Taken from Ref. [53]. 
 
Typical antidiabetic V(V) and V(IV) complexes undergo profound chemical changes in 
GI media. The main observation is that in the absence of food V(IV) is oxidized to V(V) only 
in the intestine and only the dipic dissociates (intestinal), while mal does not. While in the 
presence of food reduction of V(V) to V(IV) and even to V(III) takes place already in gastric 
environment together with the total dissociation of the original carrier ligands (Fig. 2.). The 
observed significant difference between the presence and absence of food is in a complete 
coincide with the absorption difference of BEOV between the fasted/fed subjects reported in 
Phase I trial [16]. 
As the overall bioavailability of BEOV was three times higher than that of vanadium 
from VO(IV)SO4 (Phase I[16]) it seems that passive diffusion of neutral species is the most 
effective absorption process, while the other possibilities e.g. vanadate like phosphate or 
VO(IV)2+ species via M2+ uptake mechanisms or V(III)/Fe(III) pathways are less important. 
All exogenous and endogenous biomolecules being present in the stomach or intestines, 
where the complexes are absorbed, may play a role in VO(IV) binding. Interactions with these 
molecules could change the net charge of the complex unfavorably, which will decrease their 
absorption efficacy. This certainly has to be taken into account during the formulation of the 
drug (e.g. by encapsulation techniques, whereby these problems may well be overcome), 
results of H. Sakurai et al. [43] support this prediction. In their study VO(IV)SO4 was 
administered orally in various formulations: in solution, in gelatin capsules and in enteric-
coated capsules. It was found that administration of the VO(IV) salt in encapsulated forms 
improved the metal ion absorption as compared with that associated with the simple solution 
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form. As far as we know, up to now, no such experiment has been made with vanadium 
complexes. 
These results, together with direct pharmacokinetic measurements [24] reveal that these 
antidiabetic vanadium compounds dissociate soon after oral administration and absorption 
and the vanadium part is the active metabolite responsible for the antidiabetic effects. Then 
what is the role of the carrier ligands? The most obvious answer is to enhance the absorption 
of the active component and thus to decrease the dose of vanadium. 
 
2.3. Speciation of vanadium with low molecular mass (LMM) constituents of blood serum 
After absorption during their transport in the bloodstream, (ternary) complex formation 
with the serum components, as active vanadium binders has to be considered. From among 
the LMM constituents the most potent binders e.g. lactate (1,51 mM), phosphate (1,10 mM), 
citrate (99 µM), and oxalate (9 µM) have been studied. The binding strength of other serum 
components to vanadium such as amino acids and sulfate are negligible besides these LMM 
binders. As an illustration the species distribution of the three most studied antidiabetic 
VO(IV) complex is listed in Table 2 to show the importance of these LMM serum 
constituents in VO(IV) binding. 
Table 2 Species distribution of three insulin-mimetic VO(IV) compounds (10 M) in the low 
molecular mass fraction of blood serum at pH 7.4 (Adapted from Ref. [47]) 
It is seen from the data in Table 2 that of the LMM bioligands, citrate might have a 
pronounced effect on the serum solution state of vanadium. Lactic acid and phosphate have 
minor roles and oxalate a negligible role in VO(IV) binding [47]. 
 
VO(IV) binder molecule 
(from serum) 
VO(IV)% bound 
VO(IV)(mal)2 VO(IV)(pic)2 VO(IV)(6-Me-pic)2 
In ternary complexes with     
citrate 14 42 30 
In binary complexes with    
citrate 73 50 59 
lactate 5 3 8 
phosphate 8 5 2 
 12 
2.4. Speciation of vanadium with high molecular mass (HMM) constituents of blood serum 
From among the serum proteins transferrin, albumin, immunoglobulins are the most 
important vanadium binders. In principle the metal ion can bind to these proteins in the 
oxidation states of +3, +4 and +5. Large numbers of works have been made in this field to 
clarify the interactions both qualitatively and quantitatively and the results published in 
numerous review papers [1,3,4,6,8] Binding can occur in metal-protein binary interactions, 
and in forms of ternary complexes when the carrier ligands also participate in binding. 
Stability constants of the most likely complexes formed with the HMM components of blood 
serum are listed in Table 3. 
Table 3 Stability constants (log ) for the species formed by V(III), VO(IV)2+ and V(V) ions with 
blood proteins.  
Human Serum Transferrin (apoTf)  Human Serum Albumin (HSA)  Immunoglobulin G (IgG) 
or Hemoglobin (Hb) 
Species log  Ref.  Species log  Ref.  Species log  Ref. 
V(III)apoTf 20.01.5 [54]         
VO(IV)apoTf 
13.40.2 [6]  
VO(IV)HSA 
9.10.4 [58]  VO(IV)IgG 10.31.0 [60] 
13.00.5 [55]  9.11.0. [55]  VO(IV)Hb 10.41.0 [60] 
VO(IV)(mal)apoTf 17.70.2 [6]         
    VO(IV)(mal)2HSA 17.20.1 a     
(VO(IV))2apoTf 
25.20.4 [6]  
(VO(IV))2HSA 
20.60.4 [58]     
25.50.5 [55]  20.91.0 [55]     
V(V)apoTf 6.00.1 [56]   V(V)HSA 1.80.3 [56]     
 7.50.2 [57]   3.0 [59]     
V(V)2apoTf 11.50.3 [56]         
 14.10.5 [57]         
a Calculated using data from Ref. [48,61] 
The order of affinity of the three vanadium oxidation states towards human apoTF is 
therefore: V(III)°>°VO(IV) > V(V), in the presence of carbonate and V(III) ∼ VO(IV) > 
V(V) in its absence [3]. In one type of complexes vanadium is assumed to bind at the Fe(III) 
binding site [61] and in the bis- metal complex a closed conformation is assumed for strong 
vanadium binding. Carbonate or hydrogen-carbonate is needed as synergistic anion in the 
oxidation state of +3 and +4 for strong binding [3]. Other anions as lactate can also behave as 
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synergistic in some cases [55]. A much weaker binding of the metal ion is assumed primarily 
in oxidation state of +4 through the surface His imidazole-N donor. This binding mode is 
assumed mostly in the case of the ternary VO(IV)-apoTf-carrier ligand complexes [55] (Fig. 
3). The actual donor atoms of the Fe-binding site coordinated to VO(IV) may be two of the 
four residues Asp63, Tyr95, Tyr188 and His249 of the N-terminal lobe of human apoTF, 
and/or two of residues His585, Asp392, Tyr426 and Tyr517 of the C-terminal lobe 2. In the 
case of Type 2 binding, histidine residue may be His14, His289, His349, His350, His473, 
His606 and His642. 
 
Fig. 3. Binding mode for VO(IV)-complexes to transferrins; example of BMOV. In the case of Type 1 
binding, the VO(IV) : carrier : apoTf stoichiometry is 1 : 1 : 1 or 2 : 2 : 1. Adapted from Ref. [3] and 
partly modified. 
 
HSA, a globular protein is the other important metal binding serum protein. It contains 
two strong binding sites, one at the N-terminus (NTS/ATCUN), which is specific among 
others for Cu(II) and Ni(II), and the other is the multi-metal binding site (MBS) which is 
specific among others for Zn(II), Cd(II) and Co(II). Detailed studies in the binary VO(IV)-
HSA system revealed two different metal ion binding a strong one, later assigned to the MBS 
site and a weak one, later assigned binding to side chain carboxylate of Asp/Glu or imidazole-
N of His [58]. 
Immunoglobulins are various glycoproteins (divided into different classes); among them 
only IgG occurs in high enough concentration (an average of 84 µM) to be a potential metal 
ion binder. EPR studies in the VO(IV)-IgG system revealed that the binding mode resemble to 
that of the weak binding of VO(IV)-HSA [3]. 
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Many authors revealed ternary complex formation in VO(IV)-serum protein-carrier 
ligand systems by detailed EPR and CD studies. One example of the most likely binding 
modes of these complexes is depicted in Fig. 4. 
 
Fig. 4. Mixed species VO(IV)(mal)2(Protein) formed in aqueous solution at pH 7.4, Protein indicates 
human serum albumin (HSA), immunoglobulin G (IgG) and hemoglobin(Hb). Adapted from 
Ref. [3,55]. 
 
2.5 Speciation of vanadium(IV) and vanadium(V) in blood serum 
The maximum daily oral dose in the Phase I clinical trial was 95 mg BMOV, equivalent 
to 15 mg or 0.22 mg/kg vanadium for a 70 kg person [16]. For an absorption efficacy of 30% 
[62] and an overall blood content of 5 L, if all of this vanadium enters the blood at the same 
time, the maximum concentration attainable would be ∼20 M. However, this is only a rough 
estimation, but it clearly shows a well-defined limit. In animal studies involving much higher 
doses up to 12 mg/kg vanadium, two independent research groups determined the maximum 
vanadium concentration in the blood to be 2–3 g/mL, i.e. ca. 40–60 M. The maximum 
value of the vanadium concentration in the human blood during treatment (Phase I-IIa) was 
not published [2,16]. Modeling calculations were performed in order to explore the potential 
biotransformation processes in serum [6,8]. 
The speciation [63,64] of the metal ion among the LMM and HMM components of 
blood serum, and the original carrier ligands, including mixed ligand species was calculated 
based on stability constants and concentration data at three concentration levels of antidiabetic 
compounds (1, 10 and 100 M), the results are summarized in Fig. 5. 
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Fig. 5. Speciation of various potentially antidiabetic VO(IV) compounds (A: 1 M, B: 10 M, C: 100 
M) in serum at pH 7.4. A carrier ligands, pic, mal, dhp; B and C: LMM components of the serum: 
citric acid, lactic acid, phosphate. “B” taken from Ref. [63] “A” and “C” calculated similarly based on 
the published data in Ref. [63]. 
 
In Fig. 5. the sum of the concentration of the similar type of species are depicted: VO(IV)A2: 
VO(IV) bound in the binary bis complex, (VO(IV))xBy: binary species formed with the LMM 
components of the serum, (VO(IV))xByCz: ternary species of the LMM components of the serum, 
(VO(IV))xAyBz: ternary species of an antidiabetic complex with LMM components of the serum, 
(VO(IV))xapoTf: binary species of VO(IV) with apoTf, (VO(IV))xAyapoTf: ternary species of an 
antidiabetic complex with apoTf, (VO(IV))xHSA: binary species of VO(IV) formed with HSA, 
(VO(IV))xAyHSA: ternary species of an antidiabetic complex with HSA. 
The following conclusions could be drawn: (i) It is clear that apoTf, one of the two 
important HMM binders, is much more efficient than HSA and will displace 90-95% (1 M 
and 10 M VO(IV) compound concentration levels) of the original carrier from the complex 
or will form ternary complexes with them. (ii) Only the hydroxypyridinone derivative dhp is a 
strong enough carrier to preserve a significant proportion of the VO(IV) in the original 
complex or still bound to VO(IV) in a ternary complex with apoTf. In the other two cases 
(pic, mal), the carrier ligands are completely displaced. Similar behavior can be expected 
from the VO(IV)(acac)2, as the acac ligand is much weaker metal ion binder than dhp, mal 
and pic. (iii) Among the LMM binders, citrate is the main ’active’ component, able to 
influence the solution state of these antidiabetics but only at 100 M vanadium compound 
(VO(IV)(pic)2,VO(IV)(mal)2) level, when there is no Tf enough to bind all the metal ions. 
Among the LMM components the ternary complex(es) with the original carrier ligands 
dominate(s). (iv) The HSA containing fraction is negligible at 1 M and 10 M VO(IV) 
compound concentration level, similarly to citrate, it is able to bind the metal ion (or complex) 
only when the apoTf is already saturated with VO(IV). The total vanadium containing HSA 
fraction is lower than 20% in all three cases even at 100 M vanadium compound level. (v) 
The speciation is strongly concentration dependent in the 10-100 M VO(IV) concentration 
range. 
The dominance of apoTf in VO(IV) binding was confirmed with the use of native blood 
serum measurements by ultrafiltration, separation through a 10 kDa membrane, the LMM and 
the HMM fraction bound VO(IV) was measured by atomic absorption spectroscopy method 
[8,65]. Similarly, the protein bound VO(IV) was separated by anion exchange 
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chromatography and determined by ICP-MS. Only Tf was able to bind VO(IV), the binding 
ability of the other important serum protein HSA was negligible [6]. 
Accordingly, the most important role of the carrier ligand seems to facilitate the 
absorption of VO(IV) from the GI tract, but the complexes fall apart at last in the serum. 
Pharmacokinetic investigations proved this prediction by using labeled VO(IV)(mal)2 
complexes [24]. 
It should be mentioned, that even at higher concentrations of the VO(IV) complexes, 
such as mM level, which exceed the serum level of the strongest VO(IV) binder protein Tf, 
HSA also becomes an important binder of the VO(IV) species in serum, due to its 
significantly higher concentration [63]. However, there is no real clinical importance of this 
observation, as for example in the whole blood the LC50 value of vanadate is in the 2-5 mM 
range (estimated based on [66]). 
Among several drug candidate ligands (hpno/mpno/pic/dhp), the hpno (2-
hydroxypyridine-N-oxide, the O derivate of mpno) forms the highest stability complex with 
acidic solution [56]. Based on modeling calculation it is clear that at biologically relevant 
concentrations, c(V(V)) < 10 M, the Tf is the only V(V) binder in the blood serum. Under 
such conditions, neither the carrier ligands, nor HSA nor the LMM biomolecules present in 
the serum (lactate, citrate, phosphate, Gly or His) form sufficiently strong complexes to 
compete with apoTf, even though ca. 5% of the V(V) exists as free H2VO4
– ion in solution 
[56]. As an illustration species distribution of VO2(V)-mal is depicted in Figure 6. 
 
Fig. 6. Calculated speciation of [VO2(V)mal)2]– in blood serum. The textured area represent the 
concentration range relevant to oral administration of V(V) (≤ 10 mM).Taken from Ref. [56]. 
 
2.6. Interactions of vanadium in the whole blood 
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The interaction of VO(IV) ion with hemoglobin (Hb) was studied with spectroscopic 
(EPR and UV−vis) techniques. Binding of Hb to VO(IV) in vitro was proved, and three 
unspecific sites were characterized, with the probable coordination of His−N, Asp−O−, and 
Glu−O− donors. The value of log β for VO(IV)Hb is 10.4, significantly lower than for human 
serum apoTf. In the systems with potential antidiabetic VO(IV) compounds, mixed species 
cis-VO(IV)L2(Hb) (L =mal or dhp are observed with equatorial binding of an accessible His 
residue, whereas no ternary complexes are observed with acac. The experiments of uptake of 
[VO(IV)(mal)2], [VO(IV)(dhp)2] by red blood cells indicate that the neutral compounds 
penetrate the erythrocyte membrane through passive diffusion, and percent amounts higher 
than 50% are found in the intracellular medium. The biotransformation of [VO(IV)(mal)2], 
[VO(IV)(dhp)2] inside the red blood cells was proved [60]. 
These results suggest that interactions with the red blood cells cannot be neglected in 
the transport process or the pharmacological action of the antidiabetic vanadium compounds. 
The vanadium entered the red blood cells can either be stored there and considered as a pool, 
or be deactivated by biotransformation reactions in the cytosol. This will depend on the nature 
and the extent of these biotransformation reactions [60]. 
XANES speciation studies of antidiabetic vanadium complexes in the whole blood [67] 
were carried out using the same classification method on 3D diagrams of pre-edge and edge 
parameters similarly to GI speciation (Section 2.1). The outcome in agreement with the above 
results suggests an important role of the red blood cells in the biospeciation of vanadium. 
Although it should be noted, that the applied concentration of vanadium was 1 mM, which is 
therapeutically usually not relevant, we cannot ignore the main conclusion of these two papers 
that “the role of RBCs in the metabolism of metal-containing drugs in the blood is no less 
important than that of serum proteins, such as albumin, immunoglobulins, or transferrin [67] 
 
2.7. Speciation of vanadium in the cells 
Vanadium, either in oxidation state IV or V, mainly binds to Tf in human serum 
(Section 2.4.). Accordingly, vanadium may be assumed to enter the cell through the Tf 
receptor following the iron pathway. Neutral antidiabetic complexes bound to certain proteins 
may cross membranes by passive diffusion too [60]. 
In the intracellular medium, reducing agents can redox-interact with vanadate(V). A 
frequently discussed candidate for the reduction is GSH [60,68-69]. A high intracellular 
excess of GSH increases the possibility of formation of VO(IV) and its complexation with 
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either GSH or GSSG. Both have been shown to be reasonably potent binders for VO(IV) 
[68,70-71]. Other effective reducing agents, such as NADH or ascorbate, may cause the 
formation of even V(III) species [72-73]. Hydrolytic degradation of VO(IV) may be 
responsible for the reoxidation to vanadate(V). 
Among the LMM binders, the widely distributed ATP may also be of importance [60, 
69], as it efficiently binds VO(IV) and is also present in mM concentration in cells. 
Comparing the VO(IV) complex-forming properties of ATP and GSH, it can be concluded 
that in the whole pH range ATP is a more efficient VO(IV) binder. When ATP and GSH are 
simultaneously considered as potential VO(IV) binders, GSH is not expected to be able to 
compete with ATP for binding to VO(IV). Since ATP is a strong VO(IV) binder, ATP will 
chelate the metal ion, forming binary and/or ternary complexes, and thus might somehow be 
involved in the antidiabetic action of the VO(IV) compounds. 
XANES spectroscopic studies [74] on vanadium uptake and speciation in mammalian 
cells and cell culture media were carried out also by P. Lay and coworkers, similarly to the 
other two XANES studies (GI tract/blood). In this work they experimentally proved the 
earlier criticism of some of the authors of this paper: (Section 2.1.) namely the 1.0 mM 
vanadium concentration is therapeutically irrelevant. Such conditions were toxic for the cells 
at >8 h treatments, but the authors cannot use lower vanadium concentration because of the 
X-ray fluorescence detection limit [75]. However, the conclusions of this study are that the 
easy interconversions of V(IV) and V(V) species in the cells, i.e. the antidiabetic V(V) and 
V(IV) complexes undergo profound transformations in cell culture media, and the resultant 
products are further metabolized by cultured mammalian cells. 
After vanadium enters the body and undergoes several biotransformations finally it may 
be excreted or accumulated by different tissues. Direct comparison studies between 48V-
BMOV and 48VO(IV)SO4 demonstrated a similar pattern of biodistribution to that of 
inorganic vanadium salts observed earlier: the order of relative accumulation is bone > kidney 
> liver. The absorption level is low, the bones retaining only the ca. 0.1% of an oral dose/g 
tissue 24 h after an oral dose of VO(IV)SO4, however half-life of elimination is quite long 
(>10 d for 48V in bone after a single dose 10 M by oral gavage in rats) [16]. 
 
3. Conclusions 
There has been significant progress concerning speciation of antidiabetic vanadium 
compounds in biology (in GI tract, in blood serum, in the whole blood and in the cells), 
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although there are still unknown details concerning the translocation of the complexes from 
one place to another. A recent review about the speciation of these antidiabetic vanadium 
compounds in cell culture media gives a somewhat more realistic picture the possible solution 
state of these prodrugs in biological fluids [76], however the applied concentration of 
vanadium in the most referred experimental studies (XANES: 1 mM, EPR/NMR: 0,5 mM-
1mM) is significantly higher than the therapeutically relevant concentration. 
Further questions to clarify in order to overcome the difficulties in the clinical use of 
vanadium complexes in diabetes: 
(i) In vivo studies for a deeper understanding of the mechanistic details of 
transport, targeting and mode of action of the vanadium compounds at 
therapeutically relevant concentration range. 
(ii) Further studies on the kinetics on these processes may give important 
information on the better understanding of their biological action. 
(iii) Detailed, long term toxicity measurements are necessary in order to clarify the 
accumulation, excretion process of vanadium in the body. 
As a summary we can say that vanadium compounds, if the toxic side effects can be 
overcome, and the stable, well absorbable vanadium compounds can be targeted to the 
specific tissues, when they can exert their biological actions without significant negative side 
effects, they may have a clinical application in the future. Although, we must admit that a 
rigorous analysis of the question by medical experts has led to an opposite conclusion [77]. 
Complexation of vanadium is useful only to enhance the absorption of the (pro-)drug. 
The active metabolite is the vanadium itself, probable in the oxidation state of +5, as the 
compounds dissociate before exert their antidiabetic effect(s), which is not necessarily 
sufficient or specific enough in the target cell. Our opinion is that to make a vanadium 
compound to a more applicable drug new chemical ideas are necessary to be found to increase 
the main biological effect (or the specificity) which seems to be a hard challenge. 
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